These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 36834537)

  • 1. Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance.
    Martini S; Gemma A; Ferrari M; Cosentino M; Marino F
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.
    Aziz AI; Nguyen LC; Oumeslakht L; Bensussan A; Ben Mkaddem S
    Cannabis Cannabinoid Res; 2023 Apr; 8(2):254-269. PubMed ID: 36413346
    [No Abstract]   [Full Text] [Related]  

  • 3. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cannabidiol in the treatment of epilepsy.
    Mazurkiewicz-Bełdzińska M; Zawadzka M
    Neurol Neurochir Pol; 2022; 56(1):14-20. PubMed ID: 35211946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis for the Treatment of Epilepsy: an Update.
    Gaston TE; Szaflarski JP
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol Adverse Effects and Toxicity.
    Huestis MA; Solimini R; Pichini S; Pacifici R; Carlier J; Busardò FP
    Curr Neuropharmacol; 2019; 17(10):974-989. PubMed ID: 31161980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review.
    Furgiuele A; Cosentino M; Ferrari M; Marino F
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):251-269. PubMed ID: 33492630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search of preventive strategies: novel high-CBD
    Wang B; Kovalchuk A; Li D; Rodriguez-Juarez R; Ilnytskyy Y; Kovalchuk I; Kovalchuk O
    Aging (Albany NY); 2020 Nov; 12(22):22425-22444. PubMed ID: 33221759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
    Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
    Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
    Reddy DS
    Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol goes nuclear: The role of PPARγ.
    Khosropoor S; Alavi MS; Etemad L; Roohbakhsh A
    Phytomedicine; 2023 Jun; 114():154771. PubMed ID: 36965374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol and substance use disorder: Dream or reality.
    Karimi-Haghighi S; Razavi Y; Iezzi D; Scheyer AF; Manzoni O; Haghparast A
    Neuropharmacology; 2022 Apr; 207():108948. PubMed ID: 35032495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol.
    Sunda F; Arowolo A
    FASEB J; 2020 Nov; 34(11):14083-14092. PubMed ID: 32885502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?
    Khalid S; Almalki FA; Hadda TB; Bader A; Abu-Izneid T; Berredjem M; Elsharkawy ER; Alqahtani AM
    Curr Pharm Des; 2021; 27(13):1564-1578. PubMed ID: 33267756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.
    Giacoppo S; Soundara Rajan T; Galuppo M; Pollastro F; Grassi G; Bramanti P; Mazzon E
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4906-19. PubMed ID: 26744883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Cannabidiol in Inflammation: A Review of Pre-clinical and Clinical Findings.
    Sklenárová M; Šíma M; Slanař O
    Prague Med Rep; 2023; 124(3):216-229. PubMed ID: 37736946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and legal status of cannabidiol.
    Brunetti P; Lo Faro AF; Pirani F; Berretta P; Pacifici R; Pichini S; Busardò FP
    Ann Ist Super Sanita; 2020; 56(3):285-291. PubMed ID: 32959794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.